GlaxoSmithKline plc (LON:GSK) Insider Acquires £121.52 in Stock

Paterniano Del Favero
Agosto 13, 2017

Heritage Trust Co purchased a new stake in shares of GlaxoSmithKline PLC during the first quarter worth approximately $123,000. Proficio Capital Partners LLC raised its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company's stock valued at $57,884,000 after buying an additional 1,371,490 shares during the period. Bank of America Corp DE increased its stake in shares of GlaxoSmithKline PLC by 15.8% in the first quarter. Carroll Financial Associates Inc. raised its position in GlaxoSmithKline PLC by 3.8% in the first quarter. Pnc Financial Services Group, Inc. now owns 117,287 shares with a value of $5,057,000.

Hotchkis & Wiley Capital Management LLC reports that it bought 322,700 shares in the previous quarter increasing its holdings in GlaxoSmithKline PLC by 4.3%. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59. The stock has a 50 day moving average price of GBX 1,589.13 and a 200 day moving average price of GBX 1,623.61. The stock has a market cap of $94.80 billion, a P/E ratio of 37.51 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 26th. In the last earnings report the EPS was $1.03 and is expected to be $2.85 for the current year with 2,444,000,000 shares now outstanding. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. The ex-dividend date will be on Wednesday the 9th of August 2017.

ILLEGAL ACTIVITY WARNING: "GlaxoSmithKline PLC (GSK) Shares Sold by Berkeley Capital Partners LLC" was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US & global trademark and copyright laws. The original version of this piece of content can be accessed at

Several research analysts recently issued reports on GSK shares. Finally, Liberum Capital reissued a "buy" rating and set a GBX 1,900 ($24.74) price objective on shares of GlaxoSmithKline plc in a report on Wednesday, May 31st. BNP Paribas reissued an underperform rating and issued a GBX 1,520 ($19.79) price target on shares of GlaxoSmithKline plc in a research report on Monday, April 3rd. GlaxoSmithKline plc presently has a consensus rating of Hold and a consensus price target of GBX 1,724 ($22.45). TheStreet upgraded shares of GlaxoSmithKline PLC from a "c" rating to a "b" rating in a research report on Friday, May 19th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. The stock now has a consensus rating of "Hold" and a consensus target price of $44.67.

The value of the investment in GlaxoSmithKline PLC went from $1,465,000 to $1,754,000 a change of $289,000 quarter over quarter. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare.

Want to see what other hedge funds are holding GSK?

Altre relazioni OverNewsmagazine

Discuti questo articolo